Abstracts from the 2019 Annual Scientific Meeting of the British and Irish Hypertension Society (BIHS)

Abstract

s from the 2017 Annual Scientific Meeting of the British and Irish Hypertension Society (BIHS) Journal of Human Hypertension (2017) 31, 657–686; doi:10.1038/jhh.2017.63 The Technology and Innovation Centre, University of Strathclyde, Glasgow. 11-13 September 2017 Conference Organizer: In Conference Ltd. http://bihsevents.org/ Presenting author names are underlined in the contributor lists. Sponsorship: Funding for the publication of this supplement was provided by the British and Irish Hypertension Society for the advancement of knowledge and dissemination of information concerning the pathophysiology, epidemiology, detection, investigation and treatment of arterial hypertension and related vascular diseases. O – 1 Trends for prevalence and incidence of resistant hypertension: a population based cohort study in the UK 1995-2015 Sarah-Jo Sinnott, Liam Smeeth, Elizabeth Williamson, Ian Douglas London School of Hygiene and Tropical Medicine, London, United Kingdom Introduction: There is a dearth of data on how the prevalence and incidence of resistant hypertension (RHTN), a potent risk factor for cardiovascular disease, are changing over time. Our aim was to establish epidemiological trends for RHTN in the UK from 1995 to 2015. Methods: We used a cohort study design using electronic health records from the UK Clinical Practice Research Datalink [1]. RHTN was defined as (1) concurrent use of ⩾ 3 antihypertensive drugs, uncontrolled hypertension (⩾140/90mmHg) and adherence to drug regimen or (2) concurrent use of ≥4 anti-hypertensive drugs and adherence to drug regimen. We calculated crude and age-standardised rates of incidence and prevalence. We assessed changes in trends over time using Joinpoint models and the effect of age and gender on trends over time using Poisson models. Results: 1,317,290 million patients with hypertension were included. The age-standardised incidence of RH increased from 0.98 cases/100 person years (py) (95% CI 0.92–1.04) in 1996 to a peak level of 2.19 cases/100 py (95% CI 2.15–2.24) in 2004. Incidence then fell to 0.49 cases/100 py (95% CI 0.46–0.51) in 2015. Age-standardised prevalence increased from 1.79% (95% CI 1.71–1.88) in 1995 to a peak of 8.26% (95% CI 8.19–8.32) in 2007. Prevalence then plateaued, and subsequently declined to 7.10% (95% CI 7.02–7.16) in 2015. Conclusion: Prevalent RHTN has plateaued and decreased in recent years, due to a decrease in incidence from 2004 onwards. However, RHTN is not uncommon and remains a modifiable risk factor for cardiovascular disease. Disclosure: None declared. References: 1. UK Clinical Practice Research Datalink: https://www.cprd. com/home/. O – 2 The use of four or more drugs for intensive control of blood pressure is associated with detrimental renal effects in Systolic Blood Pressure Intervention Trial (SPRINT) Linsay McCallum, Indranil Dasgupta, Alan Jardine, Sandosh Padmanabhan University of Glasgow, Glasgow, United Kingdom, Heartlands Hospital, Birmingham, United Kingdom Background: In Systolic Blood Pressure Intervention Trial (SPRINT) [1], achievement of target systolic blood pressure (SBP) in the intensive arm required a higher number of drugs and intensive treatment was associated with lower cardiovascular (CV) events and death but an increased incidence of adverse events. Methods: Number of drug classes prescribed at randomisation and at 1,2,3,6,9,12 months were used to identify distinct trajectory groups in the standard and intensive arm using Latent Class Mixed Modelling, in 8,449 participants. Cox proportional hazards (Cox-PH) models, adjusted for age, sex, SBP (area under curve [AUC] 0-12 months), prevalent cardiovascular disease (CVD), prevalent chronic 0 1 2 3 4 5 6 7 8 9 19 95 19 96 19 97 19 98 19 99 20 00 20 01 20 02 20 03 20 04 20 05 20 06 20 07 20 08 20 09 20 10 20 11 20 12 20 13 20 14 20 15 pe r 1 00 p eo pl e or p er 1 00 p er so n ye ar s Year Incidence and Prevalence of Resistant Hypertension in the UK 1995-2015 Standardised Prevalence Standardised Incidence Figure 1. [O – 1]: Incidence and Prevalence of Resistant Hypertension by year, 1995-2016. Age Standardised to 2015 hypertensive population Journal of Human Hypertension (2017) 31, 657–686 © 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved 0950-9240/17